![](https://webarchive.library.unt.edu/eot2008/20090826090146im_/http://www.cancer.gov/images/spacer.gif) |
|
Leukemia Trial Results
1. Donated Stem Cell Transplants Better than Self-transplants for Most Patients with AML (Posted: 07/23/2009) - Evidence from a meta-analysis of prospective clinical trials supports the use of donated (or allograft) stem cell transplants to treat most individuals with acute myeloid leukemia, according to the June 10, 2009, Journal of the American Medical Association.
![](https://webarchive.library.unt.edu/eot2008/20090826090146im_/http://www.cancer.gov/images/spacer.gif)
2. For Children with Leukemia, Radiation May Be Unnecessary (Posted: 07/23/2009) - Children with the most common form of leukemia can safely forego radiation therapy to prevent relapse if they are treated with chemotherapy regimens tailored to their individual needs, according to the June 25, 2009, New England Journal of Medicine.
![](https://webarchive.library.unt.edu/eot2008/20090826090146im_/http://www.cancer.gov/images/spacer.gif)
3. Rituximab Improves Outcomes for Patients With Chronic Lymphocytic Leukemia (Posted: 01/14/2009) - Advanced chronic lymphocytic leukemia patients who received the monoclonal antibody rituximab in addition to standard chemotherapy with fludarabine and cyclophosphamide (FC) had outcomes far better than those patients who received FC alone, according to studies presented December 2008 at the American Society of Hematology meeting.
![](https://webarchive.library.unt.edu/eot2008/20090826090146im_/http://www.cancer.gov/images/spacer.gif)
4. High Dose Chemotherapy Significantly Prolongs Survival for Patients with Acute Myeloid Leukemia (Posted: 11/17/2008) - Preliminary results from a large, randomized clinical trial for patients ages 16 to 60 with previously untreated acute myeloid leukemia, a cancer of the blood and bone marrow, show that patients who received a high dose of a commercially available chemotherapy drug, daunorubicin, during initial therapy lived longer than patients who received a standard dose of the same drug.
![](https://webarchive.library.unt.edu/eot2008/20090826090146im_/http://www.cancer.gov/images/spacer.gif)
5. Allogeneic (Donor) Stem-Cell Transplant Boosts Survival in Ph-Negative, Standard-Risk ALL (Posted: 01/07/2008) - In the largest-ever clinical trial of treatment for adults with acute lymphoblastic leukemia (ALL), patients with standard-risk, Philadelphia-chromosome-negative ALL lived significantly longer after chemotherapy-induced first remission when they received allogeneic (donor) stem-cell transplantation instead of continued chemotherapy, according to a Nov. 29, 2007, report issued by Blood.
1 2 3 4 Next > |
|
![](https://webarchive.library.unt.edu/eot2008/20090826090146im_/http://www.cancer.gov/images/spacer.gif) |